Welcome to our dedicated page for Ipsen Sa news (Ticker: IPSEY), a resource for investors and traders seeking the latest updates and insights on Ipsen Sa stock.
Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen announced the filing of its 2021 Universal Registration Document with the French Autorité des Marchés Financiers on 12 April 2022, registered under number D.22-0283. The document is available on ipsen.com and includes the Annual Financial Report and the Board of Directors’ Report on Corporate Governance. With total sales of €2.9bn in FY 2021, Ipsen specializes in transformative medicines across Oncology, Rare Disease, and Neuroscience, with operations in over 100 countries.
The recent press release from Ipsen, dated March 31, 2022, provides critical information regarding its share capital and voting rights. As of the stated date, Ipsen's total number of shares is 83,814,526, leading to a gross total of voting rights of 132,085,237. The net total of voting rights stands at 130,826,088, considering shares without voting rights. This data is crucial for investors who monitor shareholder dynamics and voting power within the company.
Ipsen announced a positive recommendation from the European Medicines Agency's CHMP for Cabometyx as a treatment for locally advanced or metastatic differentiated thyroid cancer (DTC) in adults. This recommendation is based on the COSMIC-311 Phase III trial, where Cabometyx showed a 78% reduction in disease progression or death compared to placebo. The objective response rate was 15% for Cabometyx versus 0% for placebo. This follows prior FDA approval in September 2021. Cabometyx is marketed in over 60 countries worldwide, addressing a critical need for new treatment options.
Ipsen has announced the development of a new electronic autoinjector for Somatuline Autogel/Somatuline Depot, aiming to enhance the patient experience for those with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome, or acromegaly. The device, built in partnership with Phillips-Medisize, is part of a €60 million investment in innovation and manufacturing. Performance and safety studies are ongoing, with the first launches expected in 2024. This fourth-generation device promises improved injection comfort for patients and caregivers.
Ipsen has reported its share capital details as of February 28, 2022. The company has a total of 83,814,526 shares, resulting in a gross total of 132,100,358 voting rights. The net total of voting rights stands at 130,837,209, considering the deduction of shares without voting rights. This announcement adheres to the French Commercial Code and regulations established by the Autorité des Marchés Financiers.
Ipsen presented new data at the ENETS 2022 conference, highlighting the benefits of Somatuline Autogel/Somatuline Depot (lanreotide) over octreotide in patients with gastroenteropancreatic neuroendocrine tumors. The PRESTO 2 survey showed significantly fewer patients experienced injection-site pain lasting over two days with Somatuline (6.0%) vs. octreotide (22.8%). Additionally, HomeLAN survey participants reported high satisfaction (95.5%) with their at-home injection experience, indicating improved patient control and comfort in treatment.
Ipsen announced the appointment of Catherine Abi-Habib as EVP Strategy, Transformation, and Digital, effective March 1, 2022. She replaces Dominique Bery, who will head the Nordics & Baltics. With over 10 years of experience in life sciences, she previously worked at McKinsey, specializing in performance transformation. CEO David Loew emphasized her expertise in digital innovation as key to Ipsen's strategy. Ipsen reported €2.9bn in sales in FY 2021 and operates globally in oncology, rare diseases, and neuroscience.
Ipsen announced updated two-year results from the Phase III CheckMate -9ER trial, demonstrating significant efficacy of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) for advanced renal cell carcinoma (aRCC). Follow-up data showed improved overall survival (37.7 months) and progression-free survival (16.6 months) compared to sunitinib. The safety profile remained consistent, with 97.2% experiencing treatment-related adverse events. Patients reported enhanced health-related quality of life benefits. The results will be presented at the ASCO GU symposium from February 17-19, 2022.
Ipsen reported robust FY 2021 results with total sales of €2.87bn, up 10.7% as reported and 12.3% at constant currency. Core operating margin improved to 35.2%, with net profit at €646.7m, a 17.8% increase. The company plans to divest its Consumer Healthcare business, valued at up to €350m, to focus on Specialty Care, which constituted 92.1% of sales. Guidance for FY 2022 anticipates over 2% sales growth, excluding Consumer Healthcare, with an updated outlook projecting a 4-6% CAGR from 2020-2024. A proposed dividend of €1.20 per share reflects a 20% increase from the previous year.
Ipsen reported on January 31, 2022, the total number of shares and voting rights regarding its share capital. The company has 83,814,526 shares outstanding, with a gross total of 132,120,082 voting rights and a net total of 130,802,629 voting rights. This update follows provisions under the French Commercial Code regarding voting rights disclosures. The gross total accounts for shares with double voting rights and treasury shares, whereas the net total excludes shares without voting rights.